Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

ClinicalTrials.gov ID: NCT02914184

Public ClinicalTrials.gov record NCT02914184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the study.

Study identification

NCT ID
NCT02914184
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,612 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
6 Weeks to 12 Weeks
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 27, 2016 (Actual)
Primary completion
Jun 27, 2018 (Actual)
Completion
Nov 26, 2018 (Actual)
Last update posted
Jul 21, 2020

2016 – 2018

United States locations

U.S. sites
19
U.S. states
10
U.S. cities
19
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35235 —
GSK Investigational Site Anaheim California 92804 —
GSK Investigational Site Paramount California 90723 —
GSK Investigational Site Sacramento California 95815 —
GSK Investigational Site San Jose California 95119 —
GSK Investigational Site Nampa Idaho 83686 —
GSK Investigational Site Newton Kansas 67114 —
GSK Investigational Site Topeka Kansas 66604 —
GSK Investigational Site Kansas City Missouri 64108 —
GSK Investigational Site Cleveland Ohio 44121 —
GSK Investigational Site Erie Pennsylvania 16506 —
GSK Investigational Site Cheraw South Carolina 29520 —
GSK Investigational Site North Charleston South Carolina 29456-9170 —
GSK Investigational Site Layton Utah 84041 —
GSK Investigational Site Murray Utah 84107 —
GSK Investigational Site Orem Utah 84057 —
GSK Investigational Site Provo Utah 84604 —
GSK Investigational Site Syracuse Utah 84075 —
GSK Investigational Site Marshfield Wisconsin 54449 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02914184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2020 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02914184 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →